| Abstract: |
| 新型降脂药前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin-kexin type 9, PCSK9)抑制剂是近年来发现的一种降低低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C)的药物，已被多项研究证实了其在防治动脉粥样硬化性心血管疾病中的积极作用，且具有良好的安全性与耐受性。本文综述PCSK9的结构功能及PCSK9抑制剂治疗动脉粥样硬化性心血管疾病的进展。 |
| Key words: 动脉粥样硬化 前蛋白转化酶枯草溶菌素9抑制剂 心血管疾病 低密度脂蛋白胆固醇 药物相互作用 |
| 通信作者: |
| DOI：10.12289/j.issn.2097-4345.24146 |
| Received:April 12, 2024 |
| AdoptTime:June 01, 2024 |
| Fund:上海市自然科学基金(21ZR1468400) |
|
| Advances in the study of PCSK9 inhibitors in treating atherosclerotic cardiovascular disease |
| YANG Leyan,YUAN Qionglan,CHENG Jianhua |
| (School of Medicine, Tongji University, Shanghai 200331, China;Department of Anatomy and Neurobiology, School of Medicine, Tongji University, Shanghai 200331, China;Department of Pharmacology, School of Medicine, Tongji University, Shanghai 200331, China) |
| Abstract: |
| The new lipid-lowering drug proprotein convertase subtilisin-kexin type 9(PCSK9) inhibitor is a kind of low-density lipoprotein cholesterol(LDL-C) decreasing drug discovered in recent years. It has been proved by multiple studies to have positive effects in the prevention and control of atherosclerotic cardiovascular diseases, with a good safety and tolerability. This paper focuses on the structure and function of PCSK9, the mechanism of action of PCSK9 inhibitors and their clinical application. |
| Key words: atherosclerosis proprotein convertase subtilisin-kexin type 9 inhibitors cardiovascular diseases low-density lipoprotein cholesterol drug interactions |
